In AML, NGS has markedly increased sensitive detection of single nucleotide variants and small indels (VAF as low as 1–5%) in TP53 exons and hotspot regions, as well as other pathogenic variants present in up to 85% of AML patients compared to only 23% of MDS patients [46]. Here, TP53 is linked to acute myeloid leukemia.